Overview

Alpha-1 Anti-Trypsin (AAT) Treatment in Acute Myocardial Infarction

Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
Acute myocardial infarction is characterized by an intense inflammatory response. The degree of the response influences clinical outcome, with 'more' inflammation promoting heart failure. In this study we plan to determine whether treatment with plasma derived alpha-1 antitrypsin will quench the inflammatory response in patients with acute ST-segment elevation myocardial infarction (STEMI).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Virginia Commonwealth University
Treatments:
Alpha 1-Antitrypsin
Protein C Inhibitor